Analysis

Fat Taxes in Europe

Fat Taxes in Europe

Although the EU probably has the legal authority to impose “fat taxes,” the policy case for doing so needs to be stronger.

Resources versus Reputation in “Voluntary Regulation”

Resources versus Reputation in “Voluntary Regulation”

Study finds states more than feds rely on economic incentives to encourage compliance.

A New Measure of the Quality of Regulatory Analysis

A New Measure of the Quality of Regulatory Analysis

Our Report Card project scores the use of regulatory analysis in agency rulemakings.

The Final Days of the Office of Thrift Supervision

The Final Days of the Office of Thrift Supervision

OTS may not deserve some criticism from its performance during the financial crisis.

Increasing Enforcement to Reduce Pollution

Increasing Enforcement to Reduce Pollution

Research finds decreased pollution after agencies take enforcement actions.

The Value of Increasing Unlicensed Spectrum

The Value of Increasing Unlicensed Spectrum

Increasing unlicensed spectrum could increase social welfare.

A Polycentric Approach to Addressing Climate Change

A Polycentric Approach to Addressing Climate Change

Law professor proposes tackling climate change with a “bottom-up” approach.

The Politics of Precaution

The Politics of Precaution

Explaining the shift in US and European approaches to risk regulation.

The Performance of Regulatory Performance Standards

The Performance of Regulatory Performance Standards

Despite their prevalence, regulatory performance standards and their efficacy have been understudied.

The Apple E-Books Litigation: A Page-Turner

The Apple E-Books Litigation: A Page-Turner

Allegations in complaints befit a conspiracy novel – one that Apple argues is completely fictional.

Do Expert Agencies Outperform Generalist Judges?

Do Expert Agencies Outperform Generalist Judges?

Empirical evidence suggests that expert agencies perform no better than courts.

Patents, Patients, and Profits: Winners and Losers in Drug Patent Challenges

Patents, Patients, and Profits: Winners and Losers in Drug Patent Challenges

Challenges to branded drugs from generic firms have benefits and costs.